Ozempic Copies at $14 in India as Novo Patent Expires

Indian drugmakers seized on the patent expiry for Novo Nordisk A/S’s blockbuster weight-loss and diabetes medication to roll out cut-price generic versions in a nation with the third-largest overweight population.